<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04791150</url>
  </required_header>
  <id_info>
    <org_study_id>ONCOIMMUNO</org_study_id>
    <nct_id>NCT04791150</nct_id>
  </id_info>
  <brief_title>Rheumatologic Adverse Events and Cancer Immunotherapy</brief_title>
  <official_title>Rheumatologic Adverse Events and Immunotherapy in Oncology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, every patient with cancer who is going to be treated by immunotherapy will&#xD;
      fill in a form. In this form, we try to determine if he presents rheumatologic complications&#xD;
      of his immunotherapy. If the patient answers yes to one question on the form, the patient&#xD;
      will be see in rheumatologic consultation to explore his clinical signs.&#xD;
&#xD;
      The number of patients referred in consultation thanks to this questionnaire will be compared&#xD;
      to the number of patients who would have been spontaneously referred by the oncologist.&#xD;
&#xD;
      The aim of this questionnaire is to optimise the management of rheumatological effects&#xD;
      secondary to immunotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Anticipated">November 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 7, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to determine whether a self-questionnaire completed by a patient treated with immunotherapy can identify more patients with rheumatological side effects related to this treatment, compared to the complaint reported by the patient to the oncologist</measure>
    <time_frame>ONE YEAR</time_frame>
    <description>number of patients referred to a rheumatology consultation thanks to the answers to the questionnaire compared to the number of patients referred to a consultation (from questionnaire and oncologist)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Oncology</condition>
  <condition>Autoimmunity</condition>
  <condition>Arthritis</condition>
  <condition>Adverse Drug Event</condition>
  <arm_group>
    <arm_group_label>Patient with cancer immunotherapy treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients starting immunotherapy treatment will complete a questionnaire to identify rheumatological side effects, each time they come for treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fill in a form</intervention_name>
    <description>Patient will have to fill in a form at each perfusion of immunotherapy to tell if they presents rheumatologic clinical signs</description>
    <arm_group_label>Patient with cancer immunotherapy treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with cancer needed to be treated by immunotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient already treated by immunotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francoise Debiais, MD PHD</last_name>
    <phone>00335 49 44 44 65</phone>
    <email>francoise.debiais@chu-poitiers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alice Bel</last_name>
    <email>alice.bel@chu-poitiers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>C.H.U de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debiais Françoise, MD</last_name>
      <phone>0033549444465</phone>
      <email>françoise.debiais@chu-poitiers.fr</email>
    </contact>
    <contact_backup>
      <last_name>Bel Alice</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>NO IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

